181 related articles for article (PubMed ID: 7826297)
21. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure.
Cantor LB; Hoop J; Katz LJ; Flartey K;
Clin Ther; 2001 Jul; 23(7):1032-9. PubMed ID: 11519768
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
23. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
[TBL] [Abstract][Full Text] [Related]
24. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
25. Effects of brimonidine on aqueous humor dynamics in human eyes.
Toris CB; Gleason ML; Camras CB; Yablonski ME
Arch Ophthalmol; 1995 Dec; 113(12):1514-7. PubMed ID: 7487618
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
27. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
28. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
[TBL] [Abstract][Full Text] [Related]
29. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
[TBL] [Abstract][Full Text] [Related]
30. Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma.
Harris A; Spaeth GL; Sergott RC; Katz LJ; Cantor LB; Martin BJ
Am J Ophthalmol; 1995 Aug; 120(2):168-75. PubMed ID: 7639300
[TBL] [Abstract][Full Text] [Related]
31. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
Carlsson AM; Chauhan BC; Lee AA; Leblanc RP
Am J Ophthalmol; 1999 Dec; 128(6):697-701. PubMed ID: 10612505
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
33. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
[TBL] [Abstract][Full Text] [Related]
34. Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers.
Jonescu-Cuypers CP; Harris A; Ishii Y; Kagemann L; Gazozi HJ; Rotenstreich Y; Chung HS; Martin B
J Ocul Pharmacol Ther; 2001 Jun; 17(3):199-205. PubMed ID: 11436940
[TBL] [Abstract][Full Text] [Related]
35. Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.
Kaufman PF
Arch Ophthalmol; 1999 May; 117(5):673-4. PubMed ID: 10326968
[No Abstract] [Full Text] [Related]
36. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.
Toris CB; Camras CB; Yablonski ME
Am J Ophthalmol; 1999 Jul; 128(1):8-14. PubMed ID: 10482088
[TBL] [Abstract][Full Text] [Related]
37. [Effect of topical 0.1% brimonidine tartrate and 0.5% timolol maleate on pulmonary and cardiovascular functions].
Araie M; Adachi M
Nippon Ganka Gakkai Zasshi; 2012 Jul; 116(7):623-34. PubMed ID: 22844781
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
Chi W; Li A; Wang S; Zhu X
Eye Sci; 2013 Dec; 28(4):190-4. PubMed ID: 24961091
[TBL] [Abstract][Full Text] [Related]
39. Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial.
Plager DA; Whitson JT; Netland PA; Vijaya L; Sathyan P; Sood D; Krishnadas SR; Robin AL; Gross RD; Scheib SA; Scott H; Dickerson JE;
J AAPOS; 2009 Aug; 13(4):384-90. PubMed ID: 19683191
[TBL] [Abstract][Full Text] [Related]
40. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
Hommer A; Kapik B; Shams N;
Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
